Taurohyodeoxycholic acid

Name: Taurohyodeoxycholic acid
Brand: MedChemExpress
SKU: HY-114360
Rating: 5.0 (2 reviews)

Cat. No.: HY-114360 Purity: 99.73%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula.

For research use only. We do not sell to patients.

Taurohyodeoxycholic acid Chemical Structure

CAS No. : 2958-04-5

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Taurohyodeoxycholic acid:

Taurohyodeoxycholic acid-d₄ sodium In-stock
Taurohyodeoxycholic acid sodium In-stock

2 Publications Citing Use of MCE Taurohyodeoxycholic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

View All TNF Receptor Isoform Specific Products:

View All Isoforms

TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	24.2 μM Compound: 10a, tauro	Agonist activity at human TGR5 expressed in CHO cells by luciferase assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay	[PMID: 18307294]

In Vitro

Taurohyodeoxycholic acid (25-100 μM, 12 h) dose-dependently decreases triglyceride levels in Palmitic acid (HY-N08307)/Oleic acid (HY-N1446)-treated AML-12 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Taurohyodeoxycholic acid (200 mg/kg, p.o., daily, 17 days) ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice by reducing lipid accumulation^[1].
Taurohyodeoxycholic acid (20-100 mg/kg, p.o. or i.g., daily, 7 days) alleviates trinitrobenzene sulfonic acid (TNBS) -induced colitis in mice^[2].
Taurohyodeoxycholic acid (4 mg/kg/min (8 μmol/min/kg), i.v., 1 h) prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	High-fat diet was fed to 4-week-old male C57BL/6 mice to induce nonalcoholic fatty liver disease^[1].
Dosage:	200 mg/kg
Administration:	p.o. daily for 17 days
Result:	Reduced body weight, liver index, and epididymal white adipose tissue index in high-fat diet-fed mice. Decreased serum triglyceride, total cholesterol, and hepatic triglyceride levels. Improved hepatic steatosis and glucose homeostasis (enhanced glucose tolerance and insulin sensitivity). Upregulated hepatic CYP7B1 protein expression and downregulated hepatic CYP7A1 and CD36 protein expressions. Dose-dependently decreased triglyceride levels in palmitic acid/oleic acid-treated AML-12 cells.

Animal Model:	Trinitrobenzene sulfonic acid (100 μL of 2.0 mg TNBS in 50% EtOH) was intrarectally administered to 7-8-week-old male SPF Kunming mice to induce ulcerative colitis^[2].
Dosage:	20, 40, 80 mg/kg
Administration:	p.o. daily for 7 days
Result:	Alleviated TNBS-induced colitis by improving body weight, colon length, spleen weight, histological characteristics, and reducing MPO activity in mice. Reduced Th1-/Th17-related cytokines (IFN-γ, IL-12, p70, IL-6, IL-17A, IL-21, IL-22, TNF-α) and transcription factors (T-bet, STAT4, RORγt, STAT3) in the colon. Increased Th2-/Treg-related cytokines (IL-4, IL-10, TGF-β1) and transcription factors (GATA3, STAT6, Foxp3, Smad3) in the colon. Inhibited IFN-γ, IL-17A, T-bet, RORγt expressions and improved IL-4, IL-10, GATA3, Foxp3 expressions in the spleen. Restored the proportion of Th1, Th2, Th17, Treg cells and balanced Th1/Th2 and Th17/Treg immune response in colitis mice.

Animal Model:	Taurochenodeoxycholic acid was intravenously infused into bile fistula Sprague-Dawley rats (200-250 g)^[3].
Dosage:	4 mg/kg/min (8 μmol/min/kg)
Administration:	i.v. for 1 h
Result:	Increased bile flow, with maximum flow rate twice that of the control group after 60 minutes. Enhanced biliary secretion of total bile acids, reaching a maximum rate of 17.5 μmol/min/kg at 60 minutes; Increased phospholipid secretion, with a peak of 0.65 μmol/min/kg. Restored biliary calcium secretion; reduced biliary leakage of alkaline phosphatase to levels similar to the control group and decreased lactate dehydrogenase leakage. Increased the maximum biliary secretion rate of taurochenodeoxycholic acid to 7.6 μmol/min/kg, with its own maximum secretion rate reaching 7.9 μmol/min/kg.

Animal Model:	Trinitrobenzene sulfonic acid (TNBS, 0.5 mg in 0.1 ml of 50% ethanol) was intrarectally administered into the colon of 22-25 g male Balb/c mice via a 3.5F catheter inserted 4 cm proximal to the anus to induce ulcerative colitis model^[4].
Dosage:	25, 50, 100 mg/kg
Administration:	i.g., daily for 7 days
Result:	Alleviated TNBS-induced colitis by improving body weight, reducing macroscopic colonic damage and histopathological changes, and decreasing colonic MPO activity in mice. Reduced serum levels of pro-inflammatory cytokines (TNF-α, IL-6) and decreased the expression of COX-2 in the colon.

Molecular Weight

499.70

Formula

C₂₆H₄₅NO₆S

CAS No.

2958-04-5

Appearance

Solid

Color

White to off-white

SMILES

C[C@@]12[C@]3([H])[C@](C[C@@H]([C@]1([H])C[C@@H](CC2)O)O)([H])[C@@]4([H])[C@](CC3)([C@@](CC4)([H])[C@H](C)CCC(NCCS(=O)(O)=O)=O)C

Structure Classification

Steroids

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (200.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0012 mL	10.0060 mL	20.0120 mL
5 mM	0.4002 mL	2.0012 mL	4.0024 mL
10 mM	0.2001 mL	1.0006 mL	2.0012 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.73%

Select Batch:

Data Sheet (282 KB) SDS (419 KB)

COA (248 KB) HNMR (337 KB) RP-HPLC (203 KB) MS (70 KB)

Handling Instructions (2659 KB)

References

[1]. Roda A, et, al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27(2):520-5. [Content Brief]

[2]. Carubbi F, et, al. Comparative cytotoxic and cytoprotective effects of taurohyodeoxycholic acid (THDCA) and tauroursodeoxycholic acid (TUDCA) in HepG2 cell line. Biochim Biophys Acta. 2002 Jan 30;1580(1):31-9. [Content Brief]

[3]. Zheng N, et al. Astragalus polysaccharide attenuates nonalcoholic fatty liver disease through THDCA in high-fat diet-fed mice. J Ethnopharmacol. 2024 Feb 10;320:117401. [Content Brief]

[4]. Lv L, et al. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Life Sci. 2023 Apr 1;318:121501. [Content Brief]

[5]. Roda A, et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. Hepatology. 1998 Feb;27(2):520-5. [Content Brief]

[6]. He J, et al. Protective effect of taurohyodeoxycholic acid from Pulvis Fellis Suis on trinitrobenzene sulfonic acid induced ulcerative colitis in mice. Eur J Pharmacol. 2011 Nov 16;670(1):229-35. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.0012 mL	10.0060 mL	20.0120 mL	50.0300 mL
	5 mM	0.4002 mL	2.0012 mL	4.0024 mL	10.0060 mL
	10 mM	0.2001 mL	1.0006 mL	2.0012 mL	5.0030 mL
	15 mM	0.1334 mL	0.6671 mL	1.3341 mL	3.3353 mL
	20 mM	0.1001 mL	0.5003 mL	1.0006 mL	2.5015 mL
	25 mM	0.0800 mL	0.4002 mL	0.8005 mL	2.0012 mL
	30 mM	0.0667 mL	0.3335 mL	0.6671 mL	1.6677 mL
	40 mM	0.0500 mL	0.2502 mL	0.5003 mL	1.2508 mL
	50 mM	0.0400 mL	0.2001 mL	0.4002 mL	1.0006 mL
	60 mM	0.0334 mL	0.1668 mL	0.3335 mL	0.8338 mL
	80 mM	0.0250 mL	0.1251 mL	0.2502 mL	0.6254 mL
	100 mM	0.0200 mL	0.1001 mL	0.2001 mL	0.5003 mL